Skip to main content
OpenTrials

Clinical trial condition

Relapsing-Remitting Multiple Sclerosis

Explore clinical trials studying Relapsing-Remitting Multiple Sclerosis. Study availability and eligibility vary by location and protocol.

97 public trials 3 recruiting studies
Refine in advanced search Browse all conditions

Relapsing-Remitting Multiple Sclerosis trial results

Completed

Biomarker Study After Initiation of Treatment With Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis

NCT01310166

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations
  • Novartis Investigative Site Ostfildern, Baden-Wurttemberg, Germany
  • Novartis Investigative Site Altenholz-Stift, Germany
  • Novartis Investigative Site Andernach, Germany
  • Novartis Investigative Site Celle, Germany
View all 61 locations
View Trial Details
Completed

Dose-finding Study of MT-1303

NCT01742052

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations
  • Research Site Brussels, Belgium
  • Research Site Sofia, Bulgaria
  • Research Site Edmonton, Canada
  • Research Site Zagreb, Croatia
View all 18 locations
View Trial Details
Completed

Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Participants With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple Sclerosis

NCT00870740

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations
  • Research Site Brno, Czechia
  • Research Site Hraddec Kralove, Czechia
  • Research Site Olomouc, Czechia
  • Research Site Pilsen, Czechia
View all 58 locations
View Trial Details
Completed

Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis

NCT01064401

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations
  • Research Site Gilbert, Arizona, United States
  • Research Site Phoenix, Arizona, United States
  • Research Site Tucson, Arizona, United States
  • Research Site Little Rock, Arkansas, United States
View all 228 locations
View Trial Details
Completed

Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing-Remitting Multiple Sclerosis

NCT00390221

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations
  • Research Site Brno, Czechia
  • Research Site Olomouc, Czechia
  • Research Site Pilsen, Czechia
  • Research Site Teplice, Czechia
View all 56 locations
View Trial Details
Completed

PK and PD Study of Natalizumab in Pediatric Subjects With RRMS

NCT01884935

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations
  • Research Site Cefalù, Italy
  • Research Site Gallarate, Italy
  • Research Site Milan, Italy
  • Research Site Padua, Italy
View Trial Details
Completed

Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADA

NCT02205489

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations
  • Investigational Site Number 056002 Bruges, Belgium
  • Investigational Site Number 056001 Brussels, Belgium
  • Investigational Site Number 250009 Dijon, France
  • Investigational Site Number 250005 Lille, France
View all 20 locations
View Trial Details
Completed

Real-world Outcomes on Tecfidera (BG00012, Dimethyl Fumarate) Post-Tysabri (BG00002, Natalizumab)

NCT02159573

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations
  • Research Site Birmingham, Alabama, United States
  • Research Site Cullman, Alabama, United States
  • Research Site Gilbert, Arizona, United States
  • Research Site Phoenix, Arizona, United States
View all 43 locations
View Trial Details

Related conditions